Results 41 to 50 of about 21,888 (191)
Even though scientific studies of smart stents are extensive, current smart stents focus on pressure sensors. This paper presents a novel implantable biocompatible smart stent for monitoring eventual restenosis.
Betsy D. M. Chaparro-Rico +2 more
doaj +1 more source
ABSTRACT Background Calcified plaque (CP) detachment (CD) and calcium fracture (CF) can occur following coronary intravascular lithotripsy (IVL). The extent to which CF alone facilitates stent expansion during CP modification with IVL remains unclear. Aims This study aimed to investigate the clinical implications of IVL‐induced CD.
Daisuke Naito +5 more
wiley +1 more source
Aim.To analyze the literature data about the role of adiponectin, P-selectin and integrin β3 in the pathogenesis of the development of in-stent restenosis in patients with coronary heart disease after coronary stenting, as well as the possibility of ...
Chernyak A. A., Snezhitskiy V. A.
doaj +1 more source
ABSTRACT Background Calcified nodules (CN) and nodular calcifications (NC) present significant challenges during percutaneous coronary intervention (PCI) because of their protruding morphology and high rigidity, which often result in inadequate stent expansion and suboptimal procedural outcomes.
Akito Setoguchi +7 more
wiley +1 more source
In 1998, 539,000 percutaneous transluminal coronary angioplasty (PTCA) procedures were performed in the United States, an increase of 248% since 1987 [1]. Most of these interventions were followed by stenting. The advent of stents has revolutionized interventional cardiology; however, the Achilles’ heel of stenting is in-stent restenosis (ISR). In this
Ali E. Denktas, Verghese Mathew
openaire +3 more sources
Introducción y objetivos: los stents convencionales presentan tasas de restenosis intrastent entre 10% y 60%, mientras los stents liberadores de fármacos alcanzan el 10%. Para Latinoamérica, no hay reportes de restenosis intrastent en comparación con los
Jorge A Arroyave C, Magda C Cepeda G
doaj
ABSTRACT Background In the REFORM trial, treatment of coronary in‐stent restenosis with a Biolimus A9™ drug‐coated balloon (BCB) was found to be inferior with respect to in‐segment percentage stenosis at 6‐months in comparison to treatment with a standard paclitaxel coated paclitaxel‐coated balloon (PCB). Aims In this manuscript, the final prespecified
Daniel O'Callaghan +18 more
wiley +1 more source
ABSTRACT Heavily calcified coronary lesions remain a major challenge in percutaneous coronary intervention (PCI), often limiting the effectiveness of intravascular lithotripsy (IVL). We report a five‐case series in which IVL failed to achieve adequate lesion modification but was successfully augmented by the addition of one or more buddy wires.
Alfredo Marchese +5 more
wiley +1 more source
Timing of silicone stent removal in patients with post-tuberculosis bronchial stenosis
Context: In patients with post-tuberculosis bronchial stenosis (PTBS), the severity of bronchial stenosis affects the restenosis rate after the silicone stent is removed.
Jung Seop Eom +8 more
doaj +1 more source
Clinical Outcomes of Drug‐Eluting Stents and Drug‐Coated Balloons in Tortuous Small Coronary Lesions
ABSTRACT Background In small, tortuous coronary lesions, the long‐term comparative performance of drug‐coated balloon (DCB) angioplasty versus drug‐eluting stent (DES) treatment remains uncertain, despite both strategies being widely used in contemporary percutaneous coronary intervention (PCI) practice. Aims This study aimed to compare 3‐year clinical
Shunichiro Ishio +6 more
wiley +1 more source

